Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of T-Dxd in the Treatment of HER2-positive Breast Cancer With Brain Metastases After Prior Pyrotinib Treatment

NCT06135194 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT06135194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06135194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of T-Dxd in the Treatment of HER2-positive Breast Cancer With Brain Metastases After Prior Pyrotinib Treatment
Lead sponsor
Beijing 302 Hospital
Phase
Observational
Overall status
Unknown status
Start date
April 1, 2021
Completion date
June 30, 2024
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer